Pavel Klener
Overview
Explore the profile of Pavel Klener including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
91
Citations
872
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Xu W, Berning P, Erdmann T, Grau M, Bettazova N, Zapukhlyak M, et al.
Leukemia
. 2022 Nov;
37(1):178-189.
PMID: 36352190
Diffuse large B-cell lymphoma (DLBCL) is an aggressive disease that exhibits constitutive activation of phosphoinositide 3-kinase (PI3K) driven by chronic B-cell receptor signaling or PTEN deficiency. Since pan-PI3K inhibitors cause...
22.
Rusconi C, Cheah C, Eyre T, Tucker D, Klener P, Gine E, et al.
Blood
. 2022 Jul;
140(17):1907-1916.
PMID: 35789260
Central nervous system (CNS) relapse of mantle cell lymphoma (MCL) is a rare phenomenon with dismal prognosis, where no standard therapy exists. Since the covalent Bruton tyrosine kinase (BTK) inhibitor...
23.
Jorda R, Havlicek L, Perina M, Vojackova V, Pospisil T, Djukic S, et al.
J Med Chem
. 2022 Jun;
65(13):8881-8896.
PMID: 35749742
3,5,7-Trisubstituted pyrazolo[4,3-]pyrimidines have been identified as potent inhibitors of cyclin-dependent kinases (CDKs), which are established drug targets. Herein, we describe their further structural modifications leading to novel nanomolar inhibitors with...
24.
Polgarova K, Polivka J, Kodet O, Klener P, Trneny M
Front Oncol
. 2022 Jun;
12:884091.
PMID: 35747818
Cutaneous T-cell lymphomas (CTCL) represent rare non-Hodgkin lymphomas (NHL) with an incidence less than 1 per 100,000 inhabitants. The most common type of CTCL is mycosis fungoides (MF), which represents...
25.
Complex genetic and histopathological study of 15 patient-derived xenografts of aggressive lymphomas
Jaksa R, Karolova J, Svaton M, Kazantsev D, Grajciarova M, Pokorna E, et al.
Lab Invest
. 2022 Apr;
102(9):957-965.
PMID: 35488033
Non-Hodgkin lymphomas (NHL) represent the most common hematologic malignancies. Patient-derived xenografts (PDXs) are used for various aspects of translational research including preclinical in vivo validation of experimental treatment approaches. While...
26.
Etrych T, Braunova A, Zogala D, Lambert L, Renesova N, Klener P
Cancers (Basel)
. 2022 Feb;
14(3).
PMID: 35158894
Malignant lymphomas represent the most common type of hematologic malignancies. The first clinically approved TDD modalities in lymphoma patients were anti-CD20 radioimmunoconjugates (RIT) I-tositumomab and Y-ibritumomab-tiuxetan. The later clinical success...
27.
Klener P, Scott Alexander M, Cullen J, Stejskal V, Sliva J, Kotlarova L, et al.
J Appl Biomed
. 2021 Dec;
18(1):1-7.
PMID: 34907706
Health status is determined by the balance of oxidants and antioxidants which protects healthy cells against the threat of internal and external risk factors. Antioxidants such as ascorbate (vitamin C,...
28.
Klanova M, Kazantsev D, Pokorna E, Zikmund T, Karolova J, Behounek M, et al.
Mol Cancer Ther
. 2021 Nov;
21(1):89-99.
PMID: 34728569
The pro-survival MCL1 protein is overexpressed in many cancers, including B-cell non-Hodgkin lymphomas (B-NHL). S63845 is a highly specific inhibitor of MCL1. We analyzed mechanisms of sensitivity/resistance to S63845 in...
29.
Curik N, Polivkova V, Burda P, Koblihova J, Laznicka A, Kalina T, et al.
Front Oncol
. 2021 Oct;
11:744373.
PMID: 34616685
Somatic mutations are a common molecular mechanism through which chronic myeloid leukemia (CML) cells acquire resistance to tyrosine kinase inhibitors (TKIs) therapy. While most of the mutations in the kinase...
30.
Klener P, Sovilj D, Renesova N, Andera L
Int J Mol Sci
. 2021 Sep;
22(18).
PMID: 34576319
Hematologic malignancies (HM) comprise diverse cancers of lymphoid and myeloid origin, including lymphomas (approx. 40%), chronic lymphocytic leukemia (CLL, approx. 15%), multiple myeloma (MM, approx. 15%), acute myeloid leukemia (AML,...